Tolaney Talks Tailored Treatment Strategies in HER2+ Breast Cancer
Season 3, Episode 37, Sep 10, 2020, 07:20 PM
In our exclusive interview, Sara M. Tolaney, MD, MPH, shared insight on how risk status is being used to tailor HER2-directed therapies to patients with early-stage HER2-positive breast cancer, key trials focused on delineating optimal deescalated and escalated treatment strategies, and ongoing research in the HER2-low setting.